All stock lists
Benitec Biopharma Inc. (NASDAQ:BNTC)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$9.04-$0.05 (-0.55%)
Market cap
$315M
Insider Score
Health Score
Analyst consensus
Listed since
Jun 24, 2014
Website
Insider Score
––Not scored
BNTC Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Sound
From BNTC’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$49.5M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $642K
- Cash
- $176.4M
- Debt / equity
- 0.00
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $178.1M
- Current liabilities
- $9.1M
- Current ratio
- 19.62
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$17.2M
- Free cash flow
- -$17.4M
Dilution & runway5 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 49.5M
- Share growth (1y)
- 19.2%
- Cash runway
- 123 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
BNTC Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | 100.00 % |
| Cost of Revenue | $0.00 | $124.00 K | $119.00 K | $120.00 K | $118.00 K | $118.00 K |
| Gross Profit | $0.00 | -$124.00 K | -$119.00 K | -$120.00 K | -$118.00 K | -$118.00 K |
| SG&A Expense | $5.86 M | $6.54 M | $7.28 M | $7.54 M | $6.43 M | $13.48 M |
| R&D Expense | $8.62 M | $9.61 M | $6.30 M | $5.83 M | $3.37 M | $3.69 M |
| Operating Expenses | $14.48 M | $14.31 M | $13.46 M | $13.26 M | $9.65 M | $9.72 M |
| Operating Income | -$14.48 M | -$14.43 M | -$13.58 M | -$13.38 M | -$9.80 M | -$9.83 M |
| Pretax Income | -$12.93 M | -$12.81 M | -$11.94 M | -$11.84 M | -$8.96 M | -$8.80 M |
| Tax Provision | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$12.93 M | -$12.81 M | -$11.94 M | -$11.84 M | -$8.96 M | -$8.80 M |
| EPS (Basic) | -$0.26 | -$0.27 | -$0.24 | -$0.26 | -$0.21 | -$0.39 |
| EPS (Diluted) | -$0.26 | -$0.27 | -$0.24 | -$0.26 | -$0.21 | -$0.39 |
| Shares Outstanding | 49.49 M | 46.56 M | 49.39 M | 45.97 M | 41.52 M | 36.21 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.